研究单位：[1]Sun Yat-sen University[2]Shanghai Miracogen Inc.[3]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400030[4]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014[5]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510000[6]Cancer Hospital of Shantou University Medical College,Shantou,Guangdong,China,515041[7]Yue Bei People's Hospital,Shaoguan,Guangdong,China,512026[8]Zhongshan City People''s Hospital,Zhongshan,Guangdong,China,528403[9]Guangxi Medical University Affiliated Tumor Hospital,Nanning,Guangxi,China,530021[10]People''s Hospital of Guangxi Zhuang Autonomous Region,Nanning,Guangxi,China,530021[11]Hainan General Hospital,Haikou,Hainan,China,570311[12]Hunan Cancer Hospital,Changsha,Hunan,China,410031[13]First Affiliated Hospital of Gannan Medical University,Ganzhou,Jiangxi,China,341001[14]Ganzhou Cancer Hospital,Ganzhou,Jiangxi,China,341005[15]Shanghai East Hospital,Shanghai,Shanghai,China,200123[16]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610041[17]Yibin Second People''s Hospital,Yibin,Sichuan,China,644000
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
